ViiV Healthcare (United Kingdom)

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

Raphael J. Landovitz, Deborah Donnell, Meredith E. Clement et al. · New England Journal of Medicine · 2021 · 773 citations · Full text

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

Susan Swindells, Jaime Andrade‐Villanueva, Gary Richmond et al. · New England Journal of Medicine · 2020 · 523 citations · Full text

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

David A. Margolis, Juan González‐García, Hans-Jürgen Stellbrink et al. · The Lancet · 2017 · 492 citations

Treatment And Prevention, Medicine, Phase 2B +8

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

Chloe Orkin, Keikawus Arastéh, Miguel Górgolas Hernández-Mora et al. · New England Journal of Medicine · 2020 · 427 citations · Full text

Comparison of Changes in Bone Density and Turnover with Abacavir‐Lamivudine versus Tenofovir‐Emtricitabine in HIV‐Infected Adults: 48‐Week Results from the ASSERT Study

Hans‐Jürgen Stellbrink, Chloe Orkin, José Ramón Arribas et al. · Clinical Infectious Diseases · 2010 · 409 citations · Full text